- Home
- CHPT vs SCTX Comparison
CHPT vs SCTX Comparison
Compare CHPT & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | SCTX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.2M | 297.2M |
| IPO Year | 2019 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CHPT | SCTX |
|---|---|---|
| Price | $11.46 | $16.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $7.50 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 879.4K | 346.2K |
| Earning Date | 12-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $411,224,000.00 | N/A |
| Revenue This Year | $7.92 | N/A |
| Revenue Next Year | $13.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.44 | $13.50 |
| 52 Week High | $12.97 | $39.60 |
Technical Indicators
Market Signals| Indicator | CHPT | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.47 | 43.27 |
| Support Level | $5.55 | $13.90 |
| Resistance Level | N/A | $22.07 |
| Average True Range (ATR) | 0.87 | 1.58 |
| MACD | 0.21 | 0.33 |
| Stochastic Oscillator | 67.74 | 52.49 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.